New York, USA - November 27, 2023 - Known for its pioneering contributions to the field of antibody engineering, Creative Biolabs will present its state-of-the-art services at booth #610, where a team of experts will be available throughout the event to discuss how their cutting-edge technologies can revolutionize the discovery and development of therapeutic antibodies.
Highlights of the exhibition will include:
* Discover the power of phage display technology
With extensive expertise and the advanced phage system (M13, T4, or T7), Creative Biolabs' scientists can construct comprehensive, high-quality libraries with a diversity of 10^8. Furthermore, to detect the interaction between the displayed protein and those other molecules or isolate specific target binders, Creative Biolabs adopts innovative biopanning strategies to select high-affinity binders or ligands that can recognize the naïve targets.
* Explore Creative Biolabs' unique mastery of de novo antibody sequencing
Based on innovative, proprietary database-assisted shotgun sequencing (DASS) technology, the team enables rapid and accurate determination of complete antibody sequences, consisting of the variable region, variable plus leader region, as well as full-length heavy- and light-chain antibody sequencing of all species, isotypes, and allotypes, and reached 100% accuracy that is insurmountable among peers.
* Learn how Creative Biolabs' custom antibody development services can accelerate therapeutic research programs
From gene expression or peptide synthesis to antibody purification and labeling, Creative Biolabs offers a full variety of services for producing unique polyclonal and monoclonal antibodies. Whether a slight quota for study or a large one for diagnostics R&D, Creative Biolabs can accommodate. The scientists do epitope prediction, peptide synthesis, protein expression, polyclonal or monoclonal antibody production, as well as antibody purification from cell culture, ascites fluid, or whole serum. They also prepare mono-specific polyclonal antibodies by ligand affinity chromatography. Importantly, the entire production cycle can be accomplished within 70 days.
By attending the conference, participants will have the opportunity to engage with Creative Biolabs' team, gain insights into their cutting-edge technologies, and explore potential collaborations. The company's commitment to pushing the boundaries of antibody engineering will be showcased through interactive presentations at their booth.
"We are excited to be part of Antibody Engineering and Therapeutics US again in 2023," said a scientist at Creative Biolabs who will be delegating. "We look forward to exchanging ideas, sharing our latest developments, and collaborating with fellow researchers and industry professionals."
Visit Creative Biolabs at booth #610 during the conference to discover how their services can empower antibody research and development.
Creative Biolabs is a leading provider of custom antibody discovery, engineering, and development services. With a diverse portfolio of innovative technologies, including phage display, de novo antibody sequencing, and custom antibody development, the company continues to drive advancements in antibody-based therapeutics.